fcb06f2b-bc4d-406d-82c3-76802c77a75b
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 78
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.560
- MYC_TARGETS_V1+0.420
- OXIDATIVE_PHOSPHORYLATION+0.380
- UNFOLDED_PROTEIN_RESPONSE+0.330
- MTORC1_SIGNALING+0.320
- FATTY_ACID_METABOLISM+0.300
- XENOBIOTIC_METABOLISM+0.250
- DNA_REPAIR+0.240
- PANCREAS_BETA_CELLS+0.230
- ADIPOGENESIS+0.220
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.530
- INTERFERON_GAMMA_RESPONSE-0.420
- TNFA_SIGNALING_VIA_NFKB-0.360
- ALLOGRAFT_REJECTION-0.310
- INFLAMMATORY_RESPONSE-0.240
- KRAS_SIGNALING_UP-0.230
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.220
- UV_RESPONSE_DN-0.220
- COMPLEMENT-0.140
- IL6_JAK_STAT3_SIGNALING-0.140
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR12475158 | — | — | 0.818 |
| 2 | R277 | — | — | 0.812 |
| 3 | X265fd2ee.a8d9.4142.bf96.86a40f37234e | — | cohortA2 | 0.802 |
| 4 | a2f13560-4d23-4ef8-8c69-a5b6279d5b21 | — | — | 0.799 |
| 5 | MDT-AP-0580 | Med | Medulloblastoma | 0.797 |
| 6 | TCGA-22-5491-01A-01R-1635-07 | — | cohortSQ2 | 0.790 |
| 7 | SRR8518383 | — | E | 0.788 |
| 8 | TCGA-CN-4730-01A-01R-1436-07 | — | — | 0.786 |
| 9 | C3N-01024 | — | cohortA1 | 0.784 |
| 10 | ERR2208967 | — | — | 0.784 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.560 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.420 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.380 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.330 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.320 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.300 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.250 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.240 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.230 | Cobimetinib | — uncovered |
| ADIPOGENESIS | 0.220 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.210 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.190 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.180 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.180 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.170 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.150 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.110 | Inavolisib | — uncovered |
| PEROXISOME | 0.110 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.090 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.070 | Remibrutinib | — uncovered |